ABSTRACT
Epidermodysplasia verruciformis (also known as Lewandowsky-Lutz dysplasia) is an extremely rare autosomal recessive genodermatosis, in which the skin is unusually sensitive to human papilloma viruses (HPV). It is associated with a high risk of developing non-melanocytic skin tumors. Treatment with keratolytic retinoids is currently considered to be the most effective therapy. Retinoids have a broad spectrum of activity and inhibit the growth of squamous cell carcinoma and other malignant tumors. We report the case of an 81-year-old woman who had been receiving prophylactic treatment with oral isotretinoin at a daily dose of 1.0-0.33â¯mg/kg bodyweight for about 18 years because of her epidermodysplasia verruciformis (HPV types 9 & 57 detected). We observed a reduction of the incidence of squamous cell carcinomas of the skin and presume a causal relationship between the treatment with this retinoid and the reduction of squamous cell carcinomas of the skin in this patient.
Subject(s)
Carcinoma, Squamous Cell , Dermatologic Agents , Epidermodysplasia Verruciformis , Isotretinoin , Skin Neoplasms , Administration, Oral , Aged, 80 and over , Carcinoma, Squamous Cell/drug therapy , Dermatologic Agents/administration & dosage , Epidermodysplasia Verruciformis/drug therapy , Female , Humans , Isotretinoin/administration & dosage , Skin Neoplasms/drug therapySubject(s)
Keratosis, Seborrheic/diagnosis , Neoplasms/diagnosis , Paraneoplastic Syndromes/diagnosis , Female , Humans , MaleSubject(s)
Arthritis, Psoriatic/complications , Arthritis, Psoriatic/drug therapy , Immunoglobulin G/adverse effects , Immunoglobulin G/therapeutic use , Immunosuppressive Agents/therapeutic use , Pyoderma Gangrenosum/chemically induced , Pyoderma Gangrenosum/pathology , Receptors, Tumor Necrosis Factor/therapeutic use , Adolescent , Antirheumatic Agents/adverse effects , Antirheumatic Agents/therapeutic use , Etanercept , Humans , Male , Treatment OutcomeABSTRACT
A 68-year-old man developed a local recurrence with multiple cutaneous and subcutaneous nodules three months after excision of a primary malignant melanoma of the temple. Despite extensive surgery and adjuvant irradiation, another local recurrence occurred. Following further local progression during dacarbazine chemotherapy, topical treatment with imiquimod was begun and the chemotherapy was changed to fotemustine. During this treatment further local progression occurred and two months later regional lymph node and distant metastasis were detected. The patient died from his tumor disease eighteen months after the first diagnosis of malignant melanoma.
Subject(s)
Aminoquinolines/therapeutic use , Facial Neoplasms/drug therapy , Facial Neoplasms/secondary , Melanoma/drug therapy , Melanoma/secondary , Skin Neoplasms/drug therapy , Aged , Antineoplastic Agents/therapeutic use , Fatal Outcome , Humans , Imiquimod , Male , Treatment FailureABSTRACT
A 62-year-old obese woman presented with a malignant melanoma (Stage la). In addition, she had disseminated telangiectatic macules on both thighs. Intensive rubbing of lesions resulted in wheals. Biopsy revealed increased numbers of mast cells. We diagnosed telangiectasia macularis eruptiva perstans, a rare clinical form of adult maculopapular cutaneous mastocytosis, a group which also includes urticaria pigmentosa. No evidence was found for systemic involvement. Possible associations with malignant tumors and the possible role of c-kit mutations both in development of melanoma and mastocytosis are discussed.
